Study the Role of Prometheus Index in Prediction of Response to Treatment in Hepatitis C Patients of Genotype 4 | ||||
| Afro-Egyptian Journal of Infectious and Endemic Diseases | ||||
| Article 1, Volume 5, Issue 4, December 2015, Page 207-217 PDF (714.46 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/aeji.2015.17841 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Mohammad N El Khashab1; Mohammad Emam1; Marian Assad2; Ahmed M Abd Elraziq1 | ||||
| 1Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt | ||||
| 2Medical Microbiology and Imunology Department, Faculty of Medicine, Zagazig University, Egypt | ||||
| Abstract | ||||
| Background and study aim : Because of pegylated interferon (Peg-IFN)/ribavirin therapy is poorly tolerated and rates of response are lower in hepatitis C virus (HCV) infected patients of genotype 4, the recognition of predictors of response is a high priority in this population. We aimed to use a baseline noninvasive index to predict early virological response (EVR) to Peg-IFN/ribavirin in HCV-infected individuals, the score included 4 variables: 2 host-related variables (IL28B SNP rs12979860 and liver stiffness) and 2 HCV-related variables (genotype and viral load). Patients and Methods: 96 treatment-naive HCV-infected patients receiving Peg-IFN/ribavirin were analysed and predictive model was used. The areas under the receiver operating characteristic (AUROC) curves (95% CI), sensitivity and specificity, as well as negative and positive predictive values, were calculated. Only individuals who had completed a course of Peg-IFN-RBV therapy were considered. Results: EVR was achieved in (60.4 %) of patients. The area under the receiver operating characteristic curve (AUROC) was 0.849 (0.762-0.914). Using three cut-off values, maximum specificity and sensitivity were 81.5% and 77.5%, respectively, with a negative predictive value for EVR of 80% and a positive predictive value of 83.6%. Seventeen individuals were misclassified using optimal cut-off values. Conclusion: The probability of achieving EVR with Peg-IFN-RBV therapy in HCV-infected patients can be reliably estimated prior to initiation of therapy using Prometheus index that includes 4 noninvasive parameters. Prometheus index represents a reliable and easily applicable tool to individually evaluate the probability of achieving an EVR to Peg-IFN/ribavirin among HCV-infected patients. | ||||
| Keywords | ||||
| interferon-α; Ribavirin; Interleukin 28B; viruses; HCV genotype; HCV viral load | ||||
|
Statistics Article View: 153 PDF Download: 376 |
||||
